Biomaterial Drug Delivery Systems for Prominent Ocular Diseases.
Avin SapowadiaDelaram GhanbariaminLibo ZhouQifa ZhouTannin A SchmidtAli TamayolYupeng ChenPublished in: Pharmaceutics (2023)
Ocular diseases, such as age-related macular degeneration (AMD) and glaucoma, have had a profound impact on millions of patients. In the past couple of decades, these diseases have been treated using conventional techniques but have also presented certain challenges and limitations that affect patient experience and outcomes. To address this, biomaterials have been used for ocular drug delivery, and a wide range of systems have been developed. This review will discuss some of the major classes and examples of biomaterials used for the treatment of prominent ocular diseases, including ocular implants (biodegradable and non-biodegradable), nanocarriers (hydrogels, liposomes, nanomicelles, DNA-inspired nanoparticles, and dendrimers), microneedles, and drug-loaded contact lenses. We will also discuss the advantages of these biomaterials over conventional approaches with support from the results of clinical trials that demonstrate their efficacy.
Keyphrases
- drug delivery
- optic nerve
- cancer therapy
- age related macular degeneration
- drug release
- clinical trial
- tissue engineering
- end stage renal disease
- newly diagnosed
- peritoneal dialysis
- emergency department
- ejection fraction
- chronic kidney disease
- bone regeneration
- randomized controlled trial
- type diabetes
- circulating tumor
- metabolic syndrome
- study protocol
- replacement therapy
- cell free
- combination therapy
- single molecule
- cataract surgery
- soft tissue
- double blind
- glycemic control